$NOVOB +5% this morning, strong Ozempic/Rybelsus. 2nd weak quarter in a row for Wegovy.
Novo Nordisk's sales increased by 26% in Danish kroner and by 16% at CER to DKK 128.9 billion in the first 9 months of 2022 globenewswire.com/news-release/2…
$NOVO Q3'22 slides
novonordisk.com/content/dam/nn…
you have to look at $NOVOB slides to get $LLY's Mounjaro Rx trend...
$NOVOB milestones
$NOVOB updated FY'22 guidance
Status of platform enabling capabilities vs therapeutic area
$NOVOB R&D & commercial portfolio
nice recap of T2D landscape & pros/cons per class
$NOVOB guiding for SELECT CVOT readout mid'23, and not Q4'22, as mentioned earlier this month in reuters piece. Unless they were referring to another trial & I mixed things up.
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.